Boisteau, Emeric
Posseme, Céline
Di Modugno, Federico http://orcid.org/0000-0001-8201-7997
Edeline, Julien http://orcid.org/0000-0002-8289-7741
Coulouarn, Cédric http://orcid.org/0000-0002-5692-9586
Hrstka, Roman http://orcid.org/0000-0002-6139-2664
Martisova, Andrea http://orcid.org/0000-0002-0081-0498
Delom, Frédéric
Treton, Xavier
Eriksson, Leif A. http://orcid.org/0000-0001-5654-3109
Chevet, Eric http://orcid.org/0000-0001-5855-4522
Lièvre, Astrid http://orcid.org/0000-0003-2118-717X
Ogier-Denis, Eric http://orcid.org/0000-0002-0057-7593
Article History
Received: 26 April 2022
Revised: 3 August 2022
Accepted: 23 August 2022
First Online: 6 September 2022
Competing interests
: EO-D, XT, and EC are founders of Thabor Therapeutics.
: According to the French regulation, patients did not oppose to the analysis, and the study was approved by the Rennes Ethics Committee (Avis no. 21.122).